GlassScriptPhysician profile
Josephine Deguzman
NPI 1043391675
$37,582.08
in general payments reported to CMS, 2019-2025
17 companies · $32K in 2025
The $32K reported for 2025 was more than what 97% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $327 · 2020: $476 · 2021: $852 · 2022: $881 · 2023: $1,238 · 2024: $1,499 · 2025: $32K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Food and Beverage: $4,785 · Travel and Lodging: $2,529 · Consulting Fee: $460 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,160.00 |
| Food and Beverage | $4,784.94 |
| Travel and Lodging | $2,528.55 |
| Consulting Fee | $460.00 |
| Education | $111.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $31,600.51 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $1,159.94 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $838.62 | 2019-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $836.26 | 2019-2025 | Invega Sustenna, Spravato |
| Vanda Pharmaceuticals INC. | $580.03 | 2020-2025 | Fanapt |
| Abbvie INC. | $491.39 | 2021-2024 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $382.06 | 2020-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Lundbeck LLC | $368.27 | 2019-2025 | Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $349.53 | 2020-2025 | Caplyta |
| Indivior INC. | $342.82 | 2019-2024 | Perseris |
| E.R. Squibb & Sons, L.L.C. | $237.74 | 2024-2025 | Cobenfy |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $175.00 | 2019 | |
| Alk-Abello, INC | $67.72 | 2022 | |
| Sunovion Pharmaceuticals INC. | $62.17 | 2021 | |
| Axsome Therapeutics, INC. | $38.21 | 2023-2024 | Auvelity |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $30.89 | 2020 | |
| Braeburn INC. | $20.92 | 2024 | Brixadi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Josephine Deguzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.